News
The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of a promising drug known as lecanemab. Just a few weeks ago the U.S.
The Pat Summitt Foundation presented a $25,000 grant to the University of Kentucky's Sanders-Brown Center on Aging (SBCoA)during the UK women’s basketball game against Auburn University on Thursday evening. The center is one of the nation’s top centers on aging, with a goal to preserve brain health and slow the progression of dementia.
The University of Kentucky’s ninth annual Healthy Hearts for Women Symposium will bring in nationally recognized experts to raise awareness about the dangers of heart disease and educate attendees on prevention techniques.
My name is Jessica Gebhardt, and I am a graduate student in Dr. Josh Morganti’s Lab studying the effects of dysregulated neuroinflammation following traumatic brain injury (TBI). TBI has personally impacted me and my family, and as a result I have been interested in furthering my understanding of the mechanisms underlying the injury for many years.
The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer’s disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as “preclinical” AD.
Donna Wilcock, PhD, wears many hats at the University of Kentucky, all of which are roles that help advance education and research in the Commonwealth, particularly in the realm of Alzheimer’s disease. Dr. Wilcock is assistant dean for biomedicine at the UK College of Medicine, as well as associate director of Sanders-Brown Center on Aging. She is also the Robert P. and Mildred A.
During Indigenous Peoples’ Month, the UK College of Medicine is highlighting historical figures who paved the way for an equitable future in medicine.
“For some reason, I really wanted fruit or savory food when I was going through treatment. Spicy, savory, salty food — that helped with my appetite,” recalls University of Kentucky chemistry doctoral student Yueming “Ronnie” Wu.
The University of Kentucky’s (UK) Sanders-Brown Center on Aging (SBCoA) will host its 12th annual Markesbery Symposium on Aging and Dementia this weekend. The event is named in honor and memory of the late William R. Markesbery, MD, founding director of the Sanders-Brown Center on Aging and Alzheimer's Disease Research Center.
The University of Kentucky Sanders-Brown Center on Aging will hold the 12th annual Markesbery Symposium on Aging and Dementia on Nov. 18 and 19. The scientific session will take place from 11 a.m. until 4:30 p.m. Friday, Nov. 18, in the Lee T. Todd Building.
Donna Wilcock, PhD, of the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) was awarded a $1.7 million National Institutes of Health grant for her lab’s exploration of adverse effects of two new Alzheimer’s disease drugs — aducanumab and lecanemab — which have been shown to slow the progression of cognitive decline.
A CD player. Lavender-infused lotion. A weighted blanket. A roll of red tape. The last things you’d expect when it comes to Alzheimer’s care. But every item was chosen for a specific purpose: to help care for a person with Alzheimer’s disease and related dementias (ADRD) through their sense of hearing, smell, feel, sight and more.
The University of Kentucky’s Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) program has received a five-year grant renewal — making this program over two decades old at the University of Kentucky.
We are pleased to announce the twelfth annual Markesbery Symposium for 2022, named in honor and memory of the late William R. Markesbery, MD, founding Director of the Sanders-Brown Center on Aging and Alzheimer's Disease Research Center. Dr.
The Alzheimer’s Association welcomes the University of Kentucky’s Donna M. Wilcock, PhD, as the new editor-in-chief of Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
I’m a fourth-year graduate student in the department of physiology in Dr. Lance Johnson’s lab. Our lab studies the different isoforms of Apolipoprotein E (ApoE) and their role in Alzheimer’s disease. ApoE4 is the greatest genetic risk factor for late-onset Alzheimer’s disease, but ApoE2 decreases an individual’s risk.
The Johnson lab studies the strongest genetic risk factor for Alzheimer’s disease (AD), apolipoprotein E (APOE). The E4 allele of APOE is carried by more than 25% of the population. A single copy of E4 increases Alzheimer’s risk 3-4 fold compared to the more common E3 allele.
LEXINGTON, Ky. (Sept. 2, 2022) — A team of researchers at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) has been awarded a $20.5 million grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
As an occupational therapist, Elizabeth Rhodus, PhD, has worked closely with older Kentuckians facing Alzheimer’s disease and related dementias (ADRD). She also has witnessed firsthand how poor health, limited resources, and high poverty rates have served as barriers to proper prevention and treatment.